- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03201822
Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans
June 26, 2017 updated by: University of California, Davis
A randomized, double-masked and cross-over dietary intervention study in healthy young adult males to evaluate the concentration of F-derived metabolites in plasma and urine after single acute intakes of F-containing drinks on four different test days.
Study Overview
Status
Completed
Conditions
Detailed Description
Flavanols (F) are plant-derived compounds commonly present in the human diet.
Examples of F-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts.
The consumption of F-containing foods and beverages has been associated with improvements in cardiovascular health.
In this context, there exists a great interest in describing the absorption, metabolism and excretion of F in humans, as it is thought that F-derived metabolites present in circulation are the mediators of F-beneficial effects in humans.
Recently, we described a series of F-derived metabolites in circulation that are present after the consumption of a single acute intake amount of F in humans.
A key question, however, is if the metabolites we observed after a single acute feeding are the same as those that occur in individuals who consume F-rich diets on a regular basis.
Studies investigating the metabolism of numerous other xenobiotics have shown that the profile of metabolites can greatly vary over time, as well as with the amount of xenobiotic ingested.
In this context, and considering that i) the amount of F-consumed from diet greatly varies among individuals, ii) recent epidemiology studies indicate that the vascular protective effects of F diets primarily occur when daily intake of F are relatively high; and iii) there is evidence of an intake amount-dependency on the vascular effects of F in dietary intervention studies; we submit it is important to assess whether or not there are F intake amount-dependent effects on the levels and profile of F-derived metabolites in humans.
This study will provide new information concerning the F-derived metabolites that may be responsible for mediating F-beneficial effects in humans.
We suggest the information that will be obtained from the outlined work will be particularly timely given ongoing discussion concerning the possible generation of dietary recommendations for F-rich foods.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Davis, California, United States, 95616
- UC Davis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- No prescription medications
- BMI 18.5 - 29.9 kg/m2
- Weight ≥ 110 pounds
- previously consumed cocoa and peanut products, with no adverse reactions
Exclusion Criteria:
- Adults unable to consent
- Prisoners
- Non-English speaking*
- BMI ≥ 30 kg/m2
- Allergies to nuts, cocoa and chocolate products
- Active avoidance of coffee and caffeinated soft drinks
- Under current medical supervision
- A history of cardiovascular disease, stroke, renal, hepatic, or thyroid disease
- History of clinically significant depression, anxiety or other psychiatric condition
- History of Raynaud's disease
- History of difficult blood draws
- Indications of substance or alcohol abuse within the last 3 years
- Current use of herbal, plant or botanical supplements (multi-vitamin/mineral supplements are allowed)
- Blood Pressure > 140/90 mm Hg
- GI tract disorders, previous GI surgery (except appendectomy)
- Self-reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food, potentially leading to bloating, cramping or gas)
- Diarrhea within the last month, or antibiotic intake within the last month
- Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or individual following diets with significant deviations from the average diet
- Metabolic panel results or complete blood counts that are outside of the normal reference range and are considered clinically relevant by the study physician
- Screening LDL ≥ 190 mg/dl for those who have 0-1 major risk factors apart from LDL cholesterol (i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL)
- Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL cholesterol (i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL).
(using NCEP calculator http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof)
- Screening LDL ≥ 130 mg/dl for those who have 2 major risk factors apart from LDL cholesterol (i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL), and a Framingham 10-year Risk Score 10-20% (Framingham risk calculated using NCEP calculator http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof)
- Cold, flu, or upper respiratory condition at screening
- Currently participating in a clinical or dietary intervention study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 100 mg of Cocoa Flavanols/70 kg BW
Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
|
Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
|
Experimental: 200 mg of Cocoa Flavanols/70 kg BW
Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
|
Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
|
Experimental: 400 mg of Cocoa Flavanols/70 kg BW
Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
|
Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
|
Experimental: 1000 mg of Cocoa Flavanols/70 kg BW
Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
|
Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in levels of gut microbiome derived metabolites in urine
Time Frame: Urine collected 12h previous to intervention and up to 24 h after intervention
|
Gut microbiome derived metabolites include conjugates of 5-(3',4'-dihydroxyphenyl)-g-valerolatone metabolites
|
Urine collected 12h previous to intervention and up to 24 h after intervention
|
Change in levels of gut microbiome derived metabolites in plasma
Time Frame: Plasma collected before (0h) and up to 6h post intervention
|
Gut microbiome derived metabolites include conjugates of 5-(3',4'-dihydroxyphenyl)-g-valerolatone
|
Plasma collected before (0h) and up to 6h post intervention
|
Change in levels of structurally related epicatechin metabolites in urine
Time Frame: Urine collected 12h previous to intervention and up to 24 h after intervention
|
Structurally related epicatechin metabolites include sulfated, glucuronidated and/or methylated metabolites of epicatechin
|
Urine collected 12h previous to intervention and up to 24 h after intervention
|
Change in levels of structurally related epicatechin metabolites in plasma
Time Frame: Plasma collected before (0h) and up to 6h post intervention
|
Structurally related epicatechin metabolites include sulfated, glucuronidated and/or methylated metabolites of epicatechin
|
Plasma collected before (0h) and up to 6h post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of pharmacokinetic (PK) parameters of metabolites Maximum Plasma Concentration (CMax)
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
PK parameters: Cmax: maximum observed concentration in plasma;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Time to Maximum Plasma Concentration
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
tmax: time to maximum concentration in plasma;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Area Under the Curve
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
AUC0-t: area under the plasma concentration-time curve from hour 0 to the last measurable concentration in plasma;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Area Under the Curve extrapolated to infinity
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
AUC0-∞: area under the plasma concentration-time curve extrapolated to infinity;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Elimination Rate Constant
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
λZ: apparent terminal elimination rate constant in plasma;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Elimination Half-Life
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
t1/2: apparent terminal elimination half-life in plasma;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Systemic Clearance
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
CL/F: systemic clearance;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Renal Clearance
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
CLR: renal clearance;sampling interval and the total interval examined;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites cumulative Amount Excreted in Feces
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
Aef(0-t): Cumulative amount excreted in the feces over each sampling interval and the total interval examined.
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites Volume of Distribution
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
Vd/F: apparent volume of distribution;
|
Before intervention (0h) and up to 24 h after intervention
|
Composite of pharmacokinetic (PK) parameters of metabolites cumulative Amount Excreted in Urine
Time Frame: Before intervention (0h) and up to 24 h after intervention
|
Aeu(0-t): cumulative amount excreted in the urine over each
|
Before intervention (0h) and up to 24 h after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Heiss C, Kleinbongard P, Dejam A, Perre S, Schroeter H, Sies H, Kelm M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol. 2005 Oct 4;46(7):1276-83. doi: 10.1016/j.jacc.2005.06.055.
- Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18.
- Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related (-)-epicatechin metabolites in humans: assessment using de novo chemically synthesized authentic standards. Free Radic Biol Med. 2012 Apr 15;52(8):1403-12. doi: 10.1016/j.freeradbiomed.2011.12.010. Epub 2011 Dec 23.
- Koster H, Halsema I, Scholtens E, Knippers M, Mulder GJ. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. Biochem Pharmacol. 1981 Sep 15;30(18):2569-75. doi: 10.1016/0006-2952(81)90584-0. No abstract available.
- McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, Coletti C, Campos H, Hollenberg NK. Hypertension, the Kuna, and the epidemiology of flavanols. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S103-9; discussion 119-21. doi: 10.1097/00005344-200606001-00003.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2013
Primary Completion (Actual)
May 25, 2013
Study Completion (Actual)
May 25, 2013
Study Registration Dates
First Submitted
June 19, 2017
First Submitted That Met QC Criteria
June 26, 2017
First Posted (Actual)
June 28, 2017
Study Record Updates
Last Update Posted (Actual)
June 28, 2017
Last Update Submitted That Met QC Criteria
June 26, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 429275
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Only researchers listed in the protocol and approved by the IRB will have access to IPD.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on 100 mg of Cocoa Flavanols/70 kg BW
-
Dr. Reddy's Laboratories LimitedCompleted
-
Janssen Research & Development, LLCCompleted
-
Hospital de ManisesMerck Sharp & Dohme LLC; Hospital Arnau de Vilanova; Hospital Universitario La... and other collaboratorsUnknown
-
Stanford UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid Withdrawal | Physical DependenceUnited States
-
Bristol-Myers SquibbCompletedMultiple MyelomaUnited States, France, Australia
-
University of California, San DiegoRecruitingSepsis | Nephrolithiasis | Urinary Tract Infection (UTI)United States
-
The Hospital for Sick ChildrenTerminated
-
PhaseBio Pharmaceuticals Inc.Completed
-
Merck Sharp & Dohme LLCCompletedSmall Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
-
Medical University of South CarolinaCompleted